

PCR|ONE

Game changing access to actionable insights



PCR|ONE maximizes access to information via:

- providing results in 15 minutes
- offering ease of use, simplified workflow
- optimum information bundles
- flexibility for care-specific scenarios

AACC


disruptive technology
competition 2019

PCR|ONE

PCR|ONE provides the fastest access to molecular diagnostic information

Ease of use enables placement in a variety of clinically-relevant locations, from Point-of-Care to centralized laboratory

1 | Load sample



2 | Insert & run




3 | Read result in 15 min



Availability of results in 15 minutes. In all clinical scenarios critical results can be delivered when needed; rapid test results allow for optimization of the patient journey.



up to 20 genetic targets in a single test




Designed for speed, multiplexing, and flexibility

Proprietary infrared amplification technology


allows for 40 cycles of real-time PCR in 7 minutes.

The ultra fast PCR technology has been tested tens of thousands of times over 8 years of development of the PCR|ONE system.


pulses of IR radiation




constant heat sink




16-well geometry




IR radiation ON



32-well geometry



IR radiation OFF



64-well geometry

Microfluidics for physical multiplexing

PCR|ONE conducts each PCR reaction in a separate micro-well and uses triplicates of each reaction for maximum robustness and accuracy.

Microfluidics for flexibility

The analyzer and cartridge offer four different types of lysis, filtering, and diverse liquid handling protocols for lysis, isolation and purification of genetic material.

PCR|ONE offers a unique combination of ease and speed of testing with high multiplexing capability:




15 minute time to result



up to 20 targets in a test



sample in - answer out



PCR|ONE is a versatile platform for development of user-specific and cost-effective point-of-use panels.

The system offers unparalleled flexibility and capacity to build simple and highly multiplexed panels.

Physical multiplexing allows for fast expansion and adaptation of the assay panels in response to changing needs and epidemiological landscape.

The ultra-fast and fully automated workflow is compatible with multiple use scenarios.

PCR|ONE offers ease of use, automation & speed that result in the development of the only **SARS-CoV-2 panel in a true POCT format.**

- CLIA-waiver compatible ease of use
- fully automated analysis in the sample-in-answer-out format
- integration of lysis, DNA isolation & purification, reverse transcription, real-time PCR, melting analysis
- 15 minute total turn-around-time (TAT)



PCR|ONE offers the fastest and most comprehensive detection and characterization of MRSA for patient triage and prevention of Healthcare Associated Infections.

MRSA screening programs are effective in reducing the rate of HAI. However, widespread use of screening for triage is inhibited by the cost of testing and the lack of sufficient pathogen characterization.

The 9-plex PCR|ONE panel is the most comprehensive and at the same time the fastest detection and characterization of MRSA.


Clinical validation results

Material		Sensitivity	Specificity
nasal swabs n=193	<i>S.aureus</i>	95.8%	92.4%
	MRSA	100%	99.4%
	PVL	100%	100%


Prevalidation tests performed in October 2019 in ALAB *laboratoria*

- All PCR|ONE results were compared to microbiological phenotypic tests.
- All *S. aureus* strains detected by microbiological classification were tested on RIDA®GENE PVL assay.

Testing panels in pipeline:



| Timeline for remaining development, regulatory submission, market launch



Following the registration in Europe, we are seeking a strategic partner for global marketing of PCR|ONE and for registration of the panels in the US.

PCR|ONE is being developed by Curiosity Diagnostics, founded in 2012 as a wholly-owned subsidiary of Scope Fluidics S.A.

Curiosity Diagnostics is driving development of PCR|ONE with a team of **40 specialists, including 9 PhDs**

- Chemistry
- Medical diagnostics
- Biochemistry
- Microbiology
- Clinical studies
- Mathematics and data analysis
- IP protection
- CAD, CAM design
- Software development and testing
- Electronics and automation

| Management team:



Prof. Piotr Garstecki

- Professor of chemistry, an entrepreneur
- International expert in microfluidic systems
- H-index 50, co-author of over 100 publications and almost 100 patents.
- Worked at/with Harvard, Princeton, U. Wisconsin, Oxford University
- Co-founder of Scope Fluidics, Curiosity Diagnostics and Bacteromic



Marcin Izydorzak

- Chemist, a specialist in physical chemistry of modern materials and photophysics
- 15 years of experience in leading R&D teams in pharmaceutical companies
- Co-author of 11 inventions, also in the category of microfluidic techniques, pharmaceutical technology and biochemistry
- Co-founder of Scope Fluidics, Curiosity Diagnostics and Bacteromic



Szymon Ruta

- Manager with over 15 years of experience in investment, restructuring, as well as merger and acquisition projects
- Investment funds managing director, responsible for a EUR125M portfolio of companies.
- Member of Management Boards and Supervisory Boards of companies listed on Warsaw Stock Exchange

Business Development Inquiries

